InvestorsHub Logo
Followers 6
Posts 1400
Boards Moderated 0
Alias Born 08/24/2014

Re: None

Tuesday, 10/24/2017 12:10:26 PM

Tuesday, October 24, 2017 12:10:26 PM

Post# of 48316
My take on Oncosec for the next year is this:

They now have a cash runway to Q3 of next year, enough runway to get them to PISCES data release.

If the results are good.....they sign a licensing deal with Merck and cash will not be a problem.

On good results I can't imagine Merck not doing a deal with Oncosec.

If they do a capital raise next year on good results it will be at a much higher share price which is good because Oncosec states that they will need substantial capital at that point for ongoing operations.

TNBC is still enrolling patients, so I see this as the next data release catalyst after SITC data on current combo study.